{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:21:16Z","timestamp":1788621676146,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract\u00a0<\/jats:title><jats:p>Ruxolitinib (RUX) is a Janus kinase 1\/2 inhibitor (JAKi) approved in the EU for treating disease\u2011related splenomegaly or symptoms in adults patients with myelofibrosis (MF). This is an interim analysis of JAKoMo, a prospective, non\u2011interventional, phase IV study in MF. Between 2012\u20132019 (cutoff March 2021), 928 patients (JAKi-na\u00efve and -pretreated) enrolled from 122 German centers. This analysis focuses on JAKi-na\u00efve patients. RUX was administered according to the Summary of Product Characteristics. Compared to the COMFORT-I, -II, and JUMP trials, patients in JAKoMo were older (median 73\u00a0years), had poorer Eastern Cooperative Oncology Group (ECOG) performance statuses (16.5% had ECOG\u2009\u2265\u20092), and were more transfusion dependent (48.5%). JAKoMo represents the more challenging patients with MF encountered outside of interventional studies. However, patients with low-risk International Prognostic Scoring System (IPSS) scores or without palpable splenomegaly were also included. Following RUX treatment, 82.5% of patients experienced rapid (\u2264\u20091\u00a0month), significant decreases in palpable spleen size, which remained durable for 24\u00a0months (60% patients). Symptom assessment scores improved significantly in Month 1 (median \u20135.2) up to Month 12 (\u20136.2). Common adverse events (AEs) were anemia (31.2%) and thrombocytopenia (28.6%). At cutoff, 54.3% of patients had terminated the study due to, death, AEs, or deterioration of health. No new safety signals were observed. Interim analysis of the JAKoMo study confirms RUX safety and efficacy in a representative cohort of real-world, elderly, JAKi-na\u00efve patients with MF. Risk scores were used in less than half of the patients to initiate RUX treatment.<\/jats:p><jats:p>Trial registration: NCT05044026; September 14, 2021.<\/jats:p>","DOI":"10.1007\/s00277-023-05458-1","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T07:01:40Z","timestamp":1696402900000},"page":"3383-3399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were na\u00efve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-561X","authenticated-orcid":false,"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-8830","authenticated-orcid":false,"given":"Lutz","family":"Jacobasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-7793","authenticated-orcid":false,"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koenigsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wehmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyck","family":"von der Heyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Gr\u00f6schl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bachhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Gro\u00dfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2857-2396","authenticated-orcid":false,"given":"Heike L.","family":"Pahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"5458_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129:667\u2013679. https:\/\/doi.org\/10.1182\/blood-2016-10-695940","journal-title":"Blood"},{"key":"5458_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061. https:\/\/doi.org\/10.1016\/s0140-6736(05)71142-9","journal-title":"Lancet"},{"key":"5458_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148. https:\/\/doi.org\/10.1038\/nature03546","journal-title":"Nature"},{"key":"5458_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/nejmoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790. https:\/\/doi.org\/10.1056\/nejmoa051113","journal-title":"N Engl J Med"},{"key":"5458_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"R Levine","year":"2005","unstructured":"Levine R, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"key":"5458_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/nejmoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405. https:\/\/doi.org\/10.1056\/nejmoa1312542","journal-title":"N Engl J Med"},{"key":"5458_CR7","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/nejmoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390. https:\/\/doi.org\/10.1056\/nejmoa1311347","journal-title":"N Engl J Med"},{"key":"5458_CR8","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270. https:\/\/doi.org\/10.1371\/journal.pmed.0030270","journal-title":"PLoS Med"},{"key":"5458_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-06-721662","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-06-721662","journal-title":"Blood"},{"key":"5458_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/nejmoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787\u2013798. https:\/\/doi.org\/10.1056\/nejmoa1110556","journal-title":"N Engl J Med"},{"key":"5458_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/nejmoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807. https:\/\/doi.org\/10.1056\/nejmoa1110557","journal-title":"N Engl J Med"},{"key":"5458_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA et al (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10:156. https:\/\/doi.org\/10.1186\/s13045-017-0527-7","journal-title":"J Hematol Oncol"},{"key":"5458_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16462","volume":"189","author":"HK Al-Ali","year":"2020","unstructured":"Al-Ali HK, Griesshammer M, Foltz L et al (2020) Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol 189:888\u2013903. https:\/\/doi.org\/10.1111\/bjh.16462","journal-title":"Br J Haematol"},{"key":"5458_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:437\u2013438. https:\/\/doi.org\/10.1038\/sj.leu.2404914","journal-title":"Leukemia"},{"key":"5458_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"5458_CR16","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/jco.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30:4098\u20134103. https:\/\/doi.org\/10.1200\/jco.2012.42.3863","journal-title":"J Clin Oncol"},{"key":"5458_CR17","unstructured":"Onkopedia guideline on primary myelofibrosis. German society of hematology and medical oncology. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/primaere-myelofibrose-pmf\/@@guideline\/html\/index.html. Accessed 1 July 2022."},{"key":"5458_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M et al (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer 16:167. https:\/\/doi.org\/10.1186\/s12885-016-2208-2","journal-title":"BMC Cancer"},{"key":"5458_CR19","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L et al (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 96:1653\u20131665. https:\/\/doi.org\/10.1007\/s00277-017-3082-y","journal-title":"Ann Hematol"},{"key":"5458_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/bjh.15839","volume":"186","author":"C Harrison","year":"2019","unstructured":"Harrison C, Mathias J, Campbell-Drew M et al (2019) UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN. Br J Haematol 186:e1\u2013e4. https:\/\/doi.org\/10.1111\/bjh.15839","journal-title":"Br J Haematol"},{"key":"5458_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","volume":"11","author":"HM Kvasnicka","year":"2018","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE et al (2018) Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol 11:42. https:\/\/doi.org\/10.1186\/s13045-018-0585-5","journal-title":"J Hematol Oncol"},{"key":"5458_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, le Coutre P et al (2016) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101:1065\u20131073. https:\/\/doi.org\/10.3324\/haematol.2016.143677","journal-title":"Haematologica"},{"key":"5458_CR23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","volume":"99","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Mesa RA (2020) Management of myelofibrosis after ruxolitinib failure. Ann Hematol 99:1177\u20131191. https:\/\/doi.org\/10.1007\/s00277-020-04002-9","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05458-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05458-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05458-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:05:37Z","timestamp":1699679137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05458-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5458"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05458-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by institutional review boards and independent ethics committees at each center (leading ethics committee: ethics committee at the medical faculty of the University of Aachen) and conducted in accordance with all local legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Patients, Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent at study inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Steffen Koschmieder reports funding from Novartis, Bristol-Myers Squibb, AOP Pharma, Janssen, Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, GSK, Abbvie; patent f\u00fcr BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, GSK, Abbvie; and other financial support (e.g. travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Bioscience, GSK, Abbvie.Susanne Isfort reports advisory board honoraria from Pfizer, Incyte, and Novartis,honoraria from Novartis, BMS, Pfizer, Incyte, Abbvie, AOP Orphan and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan.Heike Pahl reports advisory board honoraria from Novartis and AOP Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}